Preferred Label : Ozanimod Hydrochloride;
NCIt definition : The hydrochloride salt form of ozanimod, an orally bioavailable sphingosine-1-phosphate
(S1P) receptors 1 (S1PR1, S1P1) and 5 (S1PR5, S1P5) modulator, with potential anti-inflammatory
and immunomodulating activities. Upon oral administration, ozanimod selectively targets
and binds to S1PR1 on lymphocytes and induces S1PR1 internalization and degradation.
This results in the sequestration of lymphocytes in lymph nodes. By preventing egress
of lymphocytes, ozanimod reduces both the amount of circulating peripheral lymphocytes
and the infiltration of lymphocytes into target tissues. This prevents a lymphocyte-mediated
immune response and may reduce inflammation. S1PR1, a G-protein coupled receptor,
plays a key role in lymphocyte migration from lymphoid tissues. Modulation of S1PR5
by ozanimod may be neuroprotective.;
UNII : 3UPR33JAAM;
InChIKey : HAOOCAKHSFYDBU-BDQAORGHSA-N;
CAS number : 1618636-37-5; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1618636-37-5
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : Zeposia;
NCI Metathesaurus CUI : CL971949;
Origin ID : C166700;
UMLS CUI : C5238091;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_free_acid_or_base_form
- is_salt_form_of
https://www.has-sante.fr/jcms/p_3352182/fr/zeposia-ozanimod-chlorhydrate-d-rectocolite-hemorragique-rch
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
Product containing precisely ozanimod (as ozanimod hydrochloride) 920 microgram/1
each conventional release oral capsule (clinical drug)
Product containing precisely ozanimod (as ozanimod hydrochloride) 460 microgram/1
each conventional release oral capsule (clinical drug)
Product containing precisely ozanimod (as ozanimod hydrochloride) 230 microgram/1
each conventional release oral capsule (clinical drug)
Ozanimod Hydrochloride
ozanimod
adult
evaluation of the transparency committee
colitis, ulcerative
ozanimod
---
